Financial Data and Key Metrics Changes - In Q3 2025, net revenue grew by 90% to $8.1 million compared to $4.3 million in the prior year period, driven by Eversense 365 US revenue of $6.4 million and $1.7 million from outside the US [15][18] - Gross profit was $3.5 million, an increase of $7.5 million from the prior year, primarily due to improved margins on the 365-day product sales [17] - Net loss decreased to $19.5 million, or $0.43 loss per share, compared to a net loss of $24 million, or $0.77 loss per share in Q3 2024 [18] Business Line Data and Key Metrics Changes - The third quarter saw a 160% increase in new patient shipments year-over-year, contributing to the overall revenue growth [5] - New insertions increased nearly 150% year-over-year and more than 50% sequentially, reflecting accelerating adoption of Eversense 365 [6] - Approximately 60% of new patients in Q3 originated from direct-to-consumer (DTC) advertising, with 40% from healthcare provider (HCP) referrals [6] Market Data and Key Metrics Changes - The number of providers actively prescribing Eversense grew by more than 55% year-over-year, indicating broadening awareness and confidence in the 365-day system [7] - Eon Care accounted for approximately one quarter of all insertions nationwide, enhancing access and standardizing patient experience [8] Company Strategy and Development Direction - The company executed a memorandum of understanding with Ascensia Diabetes Care to reassume control of Eversense commercialization, allowing for better control over strategy and investments [4] - The CE Mark application for Eversense 365 in Europe was submitted in February, with expectations for approval before the end of 2025 [8] - The company anticipates gross margins to grow to roughly 50% in 2026 and reach approximately 70% at scale for the unified business [13][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, highlighting record new patient starts and the effectiveness of DTC marketing [24] - The company expects full-year 2025 global net revenue to be approximately $35 million, with a significant portion anticipated in Q4 due to new patient starts and reorders [19][20] - Management noted that cash utilization in 2025 is expected to be approximately $60 million, with a cash balance of $111.3 million as of September 30 [22] Other Important Information - The company is focused on expanding access to its unique system and advancing technology to simplify glucose testing for people with diabetes [13] - The transition from Ascensia is expected to enhance operational efficiency and improve margins [10][21] Q&A Session Summary Question: Can you discuss the growth opportunities in DTC? - Management noted a significant increase in switchers from existing CGM systems, with 90% of new patients coming from this group, primarily from Dexcom and Libre [28][29] Question: What is the expected timeline for the integration with Twist? - The first patients are expected to start in early Q1 2026, with a ramp-up anticipated later in the year [31][32] Question: How is the inserter network evolving? - The Eon network is crucial for expanding access, with a focus on training providers and increasing the number of inserters [36] Question: What is the status of private payers transitioning to bundled payment reimbursement? - Management expects continued transitions, with significant progress made in the first half of the year [40] Question: Can you provide an update on the CE Mark for Eversense 365? - The CE Mark application is in the final stages of review, with expectations for approval soon [72]

Financial Data and Key Metrics Changes - In Q3 2025, net revenue grew by 90% to $8.1 million compared to $4.3 million in the prior year period, driven by Eversense 365 US revenue of $6.4 million and $1.7 million from outside the US [17][20][24] - Gross profit was $3.5 million, an increase of $7.5 million from the prior year, primarily due to improved margins on 365-day product sales [18][19] - Net loss decreased to $19.5 million, or $0.43 loss per share, compared to a net loss of $24 million, or $0.77 loss per share in Q3 2024 [20] Business Line Data and Key Metrics Changes - Revenue growth was driven by a 160% increase in new patient shipments year-over-year, with new insertions increasing nearly 150% year-over-year [5][6] - Approximately 60% of new patients in Q3 originated from direct-to-consumer (DTC) advertising, with 40% from healthcare provider (HCP) referrals [6][8] - The number of providers actively prescribing Eversense grew by more than 55% year-over-year, with 75 new trained inserters added, representing a 140% increase from the same time last year [8][9] Market Data and Key Metrics Changes - The installed base of Eversense grew over 150% year-over-year and nearly 40% sequentially, reflecting accelerating adoption among patients and providers [6][8] - The DTC campaign led to a 300% increase in patient leads year-over-year and an 85% increase sequentially [5][6] - The company anticipates that the transition from Ascensia will allow it to recognize 100% of revenues, which is expected to positively impact future revenue growth [18][20] Company Strategy and Development Direction - The company executed a memorandum of understanding with Ascensia Diabetes Care to reassume control of Eversense commercialization, allowing for greater control over strategy and investments [4][10] - The company plans to continue investing in DTC marketing, primarily through social media, to drive demand and awareness [6][8] - Future product development includes the anticipated CE Mark approval for Eversense 365 in Europe, expected before the end of 2025, and the launch planned for the first half of 2026 [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing significant new patient additions and top-line growth due to expanding awareness and adoption of Eversense 365 [25][26] - The company expects full-year 2025 global net revenue to be approximately $35 million, with a strong Q4 anticipated due to new patient starts and reorders from first US 365 patients [20][22] - Management highlighted margin improvements, projecting gross profit margins to grow to roughly 50% in 2026 and approximately 70% at scale [14][23] Other Important Information - The company is focused on expanding access to its unique system and advancing technology to simplify glucose testing for people with diabetes [14][25] - The transition to resume control of Eversense commercialization is progressing well, with nearly all employees from Ascensia's US CGM business electing to join Senseonics [11][12] Q&A Session Summary Question: Follow-up on growth opportunities in DTC - Management noted a significant increase in switchers from existing CGM systems, with 90% of new patients coming from this group, primarily from Dexcom and Libre [30][31] Question: Integration with Twist insulin delivery system - The first patients are expected to start in early Q1 2026, with a ramp-up anticipated later in the year [32][34] Question: Update on inserter network evolution and reimbursement - The EonCare model is expanding, with a focus on primary care and Medicare patients, and the company is seeing growth in providers interested in institutionalizing the insertion process [38][40] Question: Update on private payers and bundled payment reimbursement - Management expects continued transitions among private payers, with significant progress made in the first half of the year [42][44] Question: Details on DTC marketing spend and its effectiveness - Increased DTC spending has shown a direct correlation with patient acquisition, though there is a need for education and conversion [62][63] Question: Revenue guidance and inventory dynamics for 2026 - The company anticipates some inventory dynamics affecting revenue recognition in 2026, but remains on track for patient growth [55][66]

Core Insights - Senseonics Holdings, Inc. reported a record-setting third quarter in 2025, with total revenue of $8.1 million, marking a 90% year-over-year increase driven by a 160% rise in new patient starts in the U.S. [1][4][9] - The company is transitioning commercial responsibility for its Eversense product line back from Ascensia Diabetes Care, which is expected to enhance control over its commercialization strategy [1][3][9]. Financial Performance - Total revenue for Q3 2025 was $8.1 million, compared to $4.3 million in Q3 2024, with U.S. revenue at $6.4 million and international revenue at $1.7 million [4][9]. - Gross profit for Q3 2025 was $3.5 million, a significant improvement from a gross loss of $(4.1) million in Q3 2024, attributed to better product margins and the absence of prior year inventory write-offs [5][8]. - Research and development expenses decreased to $7.8 million from $10.5 million year-over-year, primarily due to the completion of clinical trials for the Eversense 365 system [6]. - Selling, general, and administrative expenses rose to $15.3 million from $8.3 million, driven by increased marketing and personnel costs [7]. Market Strategy and Outlook - The company anticipates receiving CE Mark approval for Eversense 365 by the end of 2025, with a European launch expected in the first half of 2026 [3]. - Senseonics expects full-year 2025 global net revenue to reach approximately $35 million, with a projected doubling of its global patient base [11]. - The company executed a 1-for-20 reverse stock split, reducing the number of outstanding shares to approximately 41 million [9][10]. Product Development - The Eversense CGM systems are designed for continuous glucose monitoring, with Eversense 365 capable of measuring glucose levels for up to 365 days [13][14]. - The company is working towards the IDE submission for its next-generation Gemini product by the end of 2025 [3].

Core Insights - Senseonics Holdings, Inc. is set to release its third quarter 2025 financial results on November 5, 2025, after market close [1] - A conference call to discuss the financial performance will take place at 4:30 p.m. Eastern Time on the same day, with a webcast available for investors [2] Company Overview - Senseonics is a medical technology company specializing in long-term implantable continuous glucose monitoring systems aimed at improving the lives of individuals with diabetes [3] - The company's CGM systems, Eversense 365 and Eversense E3, feature a small sensor that is implanted under the skin and communicates with a smart transmitter, sending glucose data to a mobile app every 5 minutes [3]

Group 1 - The call is focused on the Eversense 365 Commercial Update, indicating a significant update regarding the company's product and market performance [1] - Jeremy Feffer from Lifesci Advisors is leading the call, emphasizing the importance of forward-looking statements related to the company's future expectations and plans [2] - The company acknowledges the presence of risks and uncertainties that could affect actual results compared to the forward-looking statements made [3] Group 2 - Tim Goodnow, President and Chief Executive of Senseonics, is participating in the call, suggesting leadership involvement in discussing the company's strategic direction [4]

Core Viewpoint - Senseonics Holdings, Inc. is transitioning the commercialization and distribution of its Eversense 365 continuous glucose monitoring system from Ascensia Diabetes Care to itself, aiming for improved growth and operational efficiency [1][2][3]. Group 1: Transition Details - The transition will take effect on January 1, 2026, with Senseonics assuming global sales, marketing, and commercialization responsibilities [2]. - Brian Hansen, currently President of CGM at Ascensia, will join Senseonics as Chief Commercial Officer on the same date [2]. - The companies are collaborating to finalize the documentation for this transition [2]. Group 2: Strategic Rationale - The decision to bring Eversense commercialization in-house is driven by the need for strategic investment and dedicated commercial efforts to respond to market demands [3]. - Senseonics believes that unifying the Eversense business will accelerate growth and realize its full potential more effectively than under the current structure [3]. Group 3: Financial Implications - Senseonics has expanded its non-dilutive debt facility with Hercules Capital to $100 million to fund its commercial organization [1]. - The company anticipates immediate revenue improvement and gross margin expansion to 50% in 2026, with a target of over 70% gross margins at scale [4]. - For the full year 2025, Senseonics expects global net revenue to be approximately $34-38 million, with a projected doubling of its global patient base [5][6]. Group 4: Conference Call - A conference call is scheduled for September 4, 2025, at 8:00 A.M. Eastern Time to discuss the commercial transition [1][7].

Financial Data and Key Metrics Changes - In Q2 2025, net revenue grew 37% to $6.6 million compared to $4.9 million in the prior year period, driven by new Eversense three sixty five insertions [22][28] - Gross profit for Q2 2025 was $3.1 million, an increase of $2.8 million from the prior year, primarily due to increased margins on the three sixty five day product and a one-time gain of $700,000 from VAT recoveries [26][27] - Net loss decreased to $14.5 million or $0.02 loss per share in Q2 2025, compared to a net loss of $20.3 million or $0.03 loss per share in Q2 2024 [27][28] Business Line Data and Key Metrics Changes - New patient starts for Eversense increased by 79% year-over-year and 37% from Q1 2025, with leads more than doubling compared to the prior year [6][8] - The consignment channel accounted for over 40% of revenue in Q2 2025, with revenue recognized at the time of procedure [25][26] - The average selling prices in the consignment channel are approximately two times the ASPs through the Ascensia direct shipment channel [26] Market Data and Key Metrics Changes - U.S. revenue for Q2 2025 was $4.9 million, while revenue outside the U.S. was $1.7 million [22] - The company expects to double the global patient base in 2025 compared to 2024, with the majority of revenue expected in Q4 due to new patient starts and reorders [28][29] Company Strategy and Development Direction - The company aims to enhance Eversense awareness and adoption through increased direct-to-consumer (DTC) marketing and expanding the EON Care network [4][5] - Plans include launching Eversense three sixty five in Europe later this year and collaborating with other companies to improve market presence [9][10] - The company is focused on developing the Gemini and Freedom systems, targeting a U.S. submission for Gemini in mid-2026 and a launch for Freedom about a year after Gemini [15][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth of Eversense, with expectations for increased patient starts and reorders as the first three sixty five adopters approach their next insertions [7][29] - The company anticipates full-year 2025 global net revenue to be approximately $34 million to $38 million, considering various factors including regulatory approval timelines and marketing spending [28][30] - Management is monitoring the impact of tariffs and expects to mitigate negative effects while maintaining favorable gross profit margins [30] Other Important Information - The company raised approximately $78 million in gross proceeds during Q2 2025, which will support ongoing initiatives and product launches [18][20] - A reverse stock split is being considered to facilitate broader investment opportunities and inclusion in indices with stock price requirements [21][22] Q&A Session Summary Question: Retention rates for Eversense - Management indicated that historical retention rates are around 75% from sensor one to two, increasing to about 85% from sensor two to three, and about 95% from sensor three and beyond [36][37] Question: Consignment channel revenue contribution - The consignment channel is expected to continue increasing as a percentage of total revenue, supported by Medicare pricing and EON Care efforts [41][42] Question: Mix of diabetics using Eversense - Currently, approximately 75% of patients using Eversense are type 2 diabetics, reflecting a shift from the initial focus on type 1 patients [47][48] Question: EON Care revenue contribution - EON Care services contribute low single-digit percentages to revenue, but this is expected to grow as the network expands [53] Question: Commercialization of the Twist pump - The company plans significant co-marketing efforts with Sequel for the Twist pump, with a formal development agreement in place [56][57] Question: CMS proposal for competitive bidding - Management confirmed that Eversense is compensated as a medical benefit under Medicare and will not be part of the competitive bidding process [66][67] Question: Timing for EON Care benefits - The company currently has around 40 professionals in the EON Care network, with plans to increase this to 50 in the next few months and double that by 2026 [68][69]

Core Insights - Senseonics Holdings, Inc. reported a 79% increase in new patient starts in the U.S. compared to the previous year, indicating strong market demand for its Eversense 365 continuous glucose monitoring system [1][9]. Financial Performance - Total revenue for Q2 2025 was $6.6 million, a 37% increase from $4.9 million in Q2 2024. U.S. revenue was $4.9 million, up from $3.0 million, while international revenue decreased slightly to $1.7 million from $1.9 million [4][9]. - Gross profit for Q2 2025 was $3.1 million, significantly higher than $0.3 million in Q2 2024, driven by improved margins on the Eversense 365 product and a one-time recovery of previously expensed value-added tax [5]. - The net loss for Q2 2025 was $14.5 million, or $0.02 per share, an improvement from a net loss of $20.3 million, or $0.03 per share, in Q2 2024, primarily due to better gross profit margins and reduced R&D costs [8][9]. Operational Highlights - The company expanded its direct-to-consumer advertising campaign, resulting in a 50% increase in leads during the first month compared to the previous three-month average [9]. - Senseonics completed the transition of providers to its Eon Care network, now including 38 providers to enhance patient access to insertions [9]. - The company entered a commercial development agreement with Sequel Med Tech to integrate its automated insulin delivery system with Eversense 365, with a launch expected in Q4 2025 [9]. Future Outlook - For the full year 2025, Senseonics expects global net revenue to be approximately $34-38 million, anticipating a doubling of its global patient base. Revenue generation is expected to be skewed towards the second half of the year [10]. - Gross margins are projected to increase throughout 2025, with expected margins between 32.5% and 37.5% for the full year [10].

Company Overview - Senseonics Holdings, Inc. is a medical technology company focused on developing and manufacturing long-term implantable continuous glucose monitoring (CGM) systems for diabetes management [3] - The company's CGM systems, Eversense 365 and Eversense E3, feature a small sensor that is implanted under the skin and communicates with a smart transmitter worn externally, sending glucose data to a mobile app every 5 minutes [3] Financial Results Announcement - Senseonics plans to release its second quarter 2025 financial results after market close on August 6, 2025 [1] - A conference call to review the company's performance for the second quarter 2025 will take place at 4:30 p.m. (Eastern Time) on the same day, with a webcast available on the company's website [2]

Core Viewpoint - Senseonics Holdings, Inc. has successfully closed a public offering of 115 million shares at a price of $0.50 per share, raising gross proceeds of $57.5 million before expenses [1][2]. Group 1: Public Offering Details - The public offering included the full exercise of an option by underwriters to purchase an additional 15 million shares [1]. - The offering was conducted under a "shelf" registration statement that became effective on September 12, 2023 [5]. - The offering was managed by TD Cowen and Barclays as joint book-running managers, with RBC Capital Markets and Lake Street as bookrunners [4]. Group 2: Private Placement with Abbott Laboratories - In conjunction with the public offering, Senseonics entered into a stock purchase agreement with Abbott Laboratories, issuing shares representing 4.99% of its outstanding common stock [3]. - Abbott acquired 40,539,265 shares for approximately $20.3 million before offering expenses [3]. Group 3: Use of Proceeds - The net proceeds from both the public offering and private placement will be used to fund the launch of Eversense 365, ongoing product development, working capital, and general corporate purposes [4][9]. Group 4: Company Overview - Senseonics is focused on developing long-term implantable continuous glucose monitoring systems aimed at improving the lives of individuals with diabetes [7]. - The company's Eversense® CGM systems feature a small sensor that is implanted under the skin and communicates with a smart transmitter, sending glucose data to a mobile app every 5 minutes [7].